Taysha Gene Therapies, Inc.
TSHA
$4.06
-$0.37-8.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.77% | -24.86% | -14.61% | 26.40% | -21.96% |
| Total Depreciation and Amortization | 3.25% | -2.12% | -6.91% | 3.40% | -8.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.24% | 10.97% | 36.34% | -70.79% | 180.64% |
| Change in Net Operating Assets | 81.09% | 148.86% | -75.16% | 55.78% | -37.37% |
| Cash from Operations | -19.74% | 8.35% | -20.28% | 15.30% | -0.52% |
| Capital Expenditure | -5,300.00% | 99.47% | -19,000.00% | 105.71% | 82.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.25% | 814.29% | -36.36% | -- | -- |
| Cash from Investing | -177.42% | 116.71% | -2,953.85% | 137.14% | 82.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 288,126.67% | -- | -- | -90.41% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -329.66% | 192.91% | -4,333.33% | 101.80% | -1,184.62% |
| Cash from Financing | -95.93% | 416,038.46% | 85.43% | -105.41% | -90.64% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -107.86% | 974.07% | -20.32% | -23.89% | -130.87% |